Diversified healthcare bellwether Johnson & Johnson (NYSE:JNJ) reported decent third quarter sales trends on October 18, though profits fell. Despite continued tepid near-term results, J&J stands out for its product and sales diversification. And though upside potential remains questionable, the stock has protected investors on the downside. Year-to-date, it is up 5% while the overall market is down about 5%.

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

Third Quarter Recap
Sales advanced 6.8% to $16 billion, though operational growth was quite modest at 2.6%. Positive currency fluctuations accounted for 4.2% of the total quarterly growth. International sales improved a healthy 8.3% organically, while positive foreign exchange movements boosted reported overseas growth to 16.4% and 57% of total sales. Domestic trends were more challenging, as sales fell 3.7% to account for 43% of total sales.

By product area, reported medical device sales rose 1.7% and represented close to 40% of the total top line. Pharmaceutical sales represented the next-largest category at more than 37% of total sales. This category saw sales jump 8.9%, as international sales rose 27.5% and offset a 6.1% domestic decline, due primarily to generic competition of bacterial-treatment drug Levaquin. Consumer sales made up the remaining 23% of sales and grew a healthy 4.9%, despite a number of remaining product recalls and "ongoing efforts to enhance quality and manufacturing systems".

A double-digit increase in selling costs and operating selling, marketing and administrative expenses sent operating income down 2.6% to $4.1 billion. Income tax expense also jumped in the double digits and sent net income down 6.3% to $3.2 billion, or $1.15 diluted earnings per share (diluted EPS). However, this still resulted in an impressive net profit margin of 20%. (To learn more about investment quality, check out: Find Investment Quality In The Income Statement.)

J&J expects to report full-year earnings between $4.95 and $5 diluted EPS, excluding the impact of special items. Analysts currently project full-year sales growth of 6% and total sales of more than $65 billion.

Bottom Line
J&J trades at a reasonable forward P/E of 13 and sports an above-average dividend yield of 3.5%. However, growth in recent years has been an issue. Over the past three years, sales have barely budged, though earnings are up close to 10% annually on average. The five-year figures show stronger annual sales growth of 4%, but weaker profit growth of below 7%.

Compared to pure-play pharmaceutical rivals including Pfizer (NYSE:PFE) and Merck (NYSE:MRK), J&J has a clearer growth profile, though this is due in good part to its non-pharma divisions. The consumer unit should eventually see a sales rebound from a surprising number of product recalls and manufacturing deficiencies. The medical device unit also continues to benefit from strong demand and acquisitions, though pure-play rival Medtronic (NYSE:MDT) currently looks like a better bet at less than 10 times forward earnings. But J&J still represents one of the best ways to play a broad array of healthcare product categories across the globe. Abbott Laboratories (NYSE:ABT) is an equally compelling play and trades at a forward P/E of just over 11.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Mutual Funds & ETFs

    What Exactly Are Arbitrage Mutual Funds?

    Learn about arbitrage funds and how this type of investment generates profits by taking advantage of price differentials between the cash and futures markets.
  2. Investing News

    Ferrari’s IPO: Ready to Roll or Poor Timing?

    Will Ferrari's shares move fast off the line only to sputter later?
  3. Stock Analysis

    5 Cheap Dividend Stocks for a Bear Market

    Here are five stocks that pay safe dividends and should be at least somewhat resilient to a bear market.
  4. Investing

    How to Win More by Losing Less in Today’s Markets

    The further you fall, the harder it is to climb back up. It’s a universal truth that is painfully apparent in the investing world.
  5. Fundamental Analysis

    Use Options Data To Predict Stock Market Direction

    Options market trading data can provide important insights about the direction of stocks and the overall market. Here’s how to track it.
  6. Stock Analysis

    2 Oil Stocks to Buy Right Now (PSX,TSO)

    Can these two oil stocks buck the trend?
  7. Investing News

    What Alcoa’s (AA) Breakup Means for Investors

    Alcoa plans to split into two companies. Is this a bullish catalyst for investors?
  8. Stock Analysis

    Top 3 Stocks for the Coming Holiday Season

    If you want to buck the bear market trend by going long on consumer stocks, these three might be your best bets.
  9. Investing News

    Could a Rate Hike Send Stocks Higher?

    A rate hike would certainly alter the investment scene, but would it be for the better or worse?
  10. Investing News

    Corporate Bonds or Stocks: Which is Better Now?

    With market volatility high, you may think it is time to run for corporate bonds instead of stocks. Before you do take a deeper look into which is better.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!